---
title: "Integrated Immunotherapy Target Atlas for Ewing Sarcoma: Translating ESS32 into Practical Targets"
id: "pubmed-42674817"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42674817"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42674817/"
doi: "10.21873/cgp.20605"
published_at: "2026-09-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Integrated Immunotherapy Target Atlas for Ewing Sarcoma: Translating ESS32 into Practical Targets
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42674817
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42674817/)
- **DOI:** [10.21873/cgp.20605](https://doi.org/10.21873%2Fcgp.20605)
- **Published At:** 2026-09-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Ewing sarcoma is a **fusion-driven malignancy** with low tumor mutational burden, making identification of recurrent tumor-associated antigens with good tumor-to-normal contrast essential for immunotherapy development. - The Deng et al. 32-gene **Ewing Sarcoma Specific Signature (ESS32)** was re-evaluated and expanded into a 38-gene analysis set that included six comparator antigens (STEAP1, LINGO1, PRAME, CD99, CD276/B7-H3, ENPP1). - Eight GEO datasets (total n = 854 samples) were analyzed across predefined roles: tumor-versus-skeletal-muscle comparison, broad normal-organ context, EWSR1::FLI1 perturbation, tumor-only support cohorts, cell-line models, and cross-sarcoma comparison. - Results were integrated with **Human Protein Atlas** and published proteomic/surfaceome evidence to add protein-level and subcellular localization context to RNA expression findings. - In dataset GSE17674, top tumor-enriched transcripts included **NKX2-2**, **NPY1R**, **STEAP1**, **RBM11**, **RNF182**, **LIPI**, **CD99**, **STEAP2**, **LOXHD1**, and **DCDC2**. - Incorporating normal-tissue distribution and compartment data materially changed the RNA-only ranking of candidate targets, highlighting the need for multi-layered evidence before nomination. - **NKX2-2** had the strongest Ewing-associated RNA signal but is a nuclear transcription factor, suggesting suitability for peptide-HLA/T-cell receptor (TCR) or vaccine approaches rather than antibody-based modalities. - **RBM11** and **LIPI** were identified as high-interest intracellular/secretome-associated candidates; LIPI has a specific epididymal/male reproductive expression caveat. - Surface or receptor targets such as **CD99** and **NPY1R** revealed normal-cell reservoir and receptor-distribution constraints that may limit therapeutic windows for certain modalities like CAR or ADC. - The author emphasizes that ESS32 is an RNA discovery set tied to **EWSR1::FLI1** biology and is not a pre-validated target panel; practical target nomination must integrate RNA enrichment, normal-tissue distribution, protein evidence, cellular compartment, and modality compatibility. - The review frames selection for TCR, vaccine, ADC, CAR, radioligand, or validation-first candidates as a process requiring layered evidence rather than RNA expression alone.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42674817/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674817%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42674817/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42674817/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42674817/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42674817/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42674817/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674817%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674817%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42674817/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674817/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674817/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42674817/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674817/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42674817/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42674817/#abstract) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42674817/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42674817/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42674817/#substances) Title & authors Abstract Publication types MeSH terms Substances Review Cancer Genomics Proteomics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Genomics+Proteomics%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer+Genomics+Proteomics%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) . 2026 Sep-Oct;23(5):856-879. doi: 10.21873/cgp.20605. # Integrated Immunotherapy Target Atlas for Ewing Sarcoma [Corey Goldman](https://pubmed.ncbi.nlm.nih.gov/?term=Goldman+C&cauthor_id=42674817)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674817/#full-view-affiliation-1 "Medalliance Medical Health Services, Bronx, NY, U.S.A.; corey.goldman@nyulangone.org.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674817/#full-view-affiliation-2 "NYU Langone Health, New York, NY, U.S.A.") Affiliations Expand ### Affiliations * 1 Medalliance Medical Health Services, Bronx, NY, U.S.A.; corey.goldman@nyulangone.org. * 2 NYU Langone Health, New York, NY, U.S.A. * PMID: **42674817** * DOI: [ 10.21873/cgp.20605 ](https://doi.org/10.21873/cgp.20605) Item in Clipboard Review # Integrated Immunotherapy Target Atlas for Ewing Sarcoma Corey Goldman. Cancer Genomics Proteomics. 2026 Sep-Oct. Show details Display options Display options Format Abstract PubMed PMID Cancer Genomics Proteomics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Genomics+Proteomics%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer+Genomics+Proteomics%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) . 2026 Sep-Oct;23(5):856-879. doi: 10.21873/cgp.20605. ### Author [Corey Goldman](https://pubmed.ncbi.nlm.nih.gov/?term=Goldman+C&cauthor_id=42674817)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674817/#short-view-affiliation-1 "Medalliance Medical Health Services, Bronx, NY, U.S.A.; corey.goldman@nyulangone.org.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674817/#short-view-affiliation-2 "NYU Langone Health, New York, NY, U.S.A.") ### Affiliations * 1 Medalliance Medical Health Services, Bronx, NY, U.S.A.; corey.goldman@nyulangone.org. * 2 NYU Langone Health, New York, NY, U.S.A. * PMID: **42674817** * DOI: [ 10.21873/cgp.20605 ](https://doi.org/10.21873/cgp.20605) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Background/aim:** Ewing sarcoma is a fusion-driven malignancy with low tumor mutational burden, making recurrent tumor-associated antigens with favorable tumor-to-normal contrast central to immunotherapy development. We converted the Deng _et al._ -defined 32-gene Ewing Sarcoma Specific Signature (ESS32) into a practical target atlas by integrating tumor RNA expression with normal-tissue context, protein evidence, subcellular localization, and therapeutic accessibility. **Materials and methods:** A 38-gene set was analyzed, including ESS32 and six comparator antigens (STEAP1, LINGO1, PRAME, CD99, CD276/B7-H3, and ENPP1). Eight Gene Expression Omnibus datasets (_n_ =854 samples) were assigned predefined roles spanning tumor-_versus_ -skeletal-muscle comparison, broad normal-organ context, EWSR1::FLI1 perturbation, tumor-only support cohorts, cell-line models, and cross-sarcoma comparison. Results were overlaid with Human Protein Atlas and published proteomic/surfaceome evidence. **Results:** In GSE17674, the strongest tumor-enriched transcripts included NKX2-2, NPY1R, STEAP1, RBM11, RNF182, LIPI, CD99, STEAP2, LOXHD1, and DCDC2. Normal-tissue and compartment data substantially reordered RNA-only ranking. NKX2-2 showed the strongest Ewing-associated signal but encodes a nuclear transcription factor, favoring peptide-HLA/T-cell receptor (TCR) or vaccine development. RBM11 and LIPI emerged as high-interest intracellular/secretome-associated candidates, with an explicit epididymal/male reproductive caveat for LIPI. CD99 and NPY1R illustrated normal-cell reservoir and receptor-distribution constraints. **Conclusion:** ESS32 should be interpreted as an EWSR1::FLI1-associated RNA discovery set, not as a pre-validated target panel. Practical nomination requires integration of RNA enrichment, normal-tissue distribution, protein evidence, cellular compartment, and modality compatibility before nomination of TCR, vaccine, antibody-drug conjugate (ADC), chimeric antigen receptor (CAR), radioligand, or validation-first candidates. **Keywords:** CAR T; ESS32; EWSR1::FLI1; Ewing sarcoma; GEO; Human Protein Atlas; antibody-drug conjugate; immunotherapy target atlas; peptide-HLA; review. Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) ## MeSH terms * Biomarkers, Tumor* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biomarkers%2C+Tumor%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Biomarkers%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Bone Neoplasms* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bone+Neoplasms%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Bone+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Bone Neoplasms* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bone+Neoplasms%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Bone+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Bone Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bone+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Bone+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Bone Neoplasms* / therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bone+Neoplasms%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Bone+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Gene Expression Profiling Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gene+Expression+Profiling%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gene+Expression+Profiling) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Gene Expression Regulation, Neoplastic Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gene+Expression+Regulation%2C+Neoplastic%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gene+Expression+Regulation%2C+Neoplastic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Homeobox Protein Nkx-2.2 Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Homeobox+Protein+Nkx-2.2%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Homeobox+Protein+Nkx-2.2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Homeodomain Proteins Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Homeodomain+Proteins%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Homeodomain+Proteins) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Immunotherapy* / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunotherapy%2Fmethods%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunotherapy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Nuclear Proteins Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Nuclear+Proteins%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Nuclear+Proteins) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Sarcoma, Ewing* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sarcoma%2C+Ewing%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Sarcoma%2C+Ewing) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Sarcoma, Ewing* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sarcoma%2C+Ewing%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Sarcoma%2C+Ewing) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Sarcoma, Ewing* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sarcoma%2C+Ewing%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Sarcoma%2C+Ewing) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Sarcoma, Ewing* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sarcoma%2C+Ewing%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Sarcoma%2C+Ewing) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Sarcoma, Ewing* / therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sarcoma%2C+Ewing%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Sarcoma%2C+Ewing) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Transcription Factors Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Transcription+Factors%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Transcription+Factors) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Zebrafish Proteins Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zebrafish+Proteins%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Zebrafish+Proteins) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) ## Substances * Homeobox Protein Nkx-2.2 Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Homeobox+Protein+Nkx-2.2%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Homeobox+Protein+Nkx-2.2%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * NKX2-2 protein, human Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22NKX2-2+protein%2C+human%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22NKX2-2+protein%2C+human%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Biomarkers, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biomarkers%2C+Tumor%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Biomarkers%2C+Tumor%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * nkx2.2b protein, zebrafish Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22nkx2.2b+protein%2C+zebrafish%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22nkx2.2b+protein%2C+zebrafish%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Nuclear Proteins Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Nuclear+Proteins%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Nuclear+Proteins%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Transcription Factors Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Transcription+Factors%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Transcription+Factors%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Homeodomain Proteins Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Homeodomain+Proteins%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Homeodomain+Proteins%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) * Zebrafish Proteins Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zebrafish+Proteins%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Zebrafish+Proteins%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674817/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42674817/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674817%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42674817/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674817%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674
## Related Clinical Research

- [Ambient light during sample processing causes verteporfin-driven protein cross-linking](https://medichelpline.com/clinical-feed/plos-one-17-ambient-light-drives-verteporfin-induced-protein-cross-linking-during-standard.md)
- [HHS and FDA push to reduce animal testing, endorse human-based research methods](https://medichelpline.com/clinical-feed/stat-news-0-stat-hhs-unveils-new-initiatives-to-reduce-animal-testing-in-drug-development.md)
- [Association of DMFT Index and Diabetes Mellitus in Central Sudan Adults — Community Study](https://medichelpline.com/clinical-feed/pubmed-42770630.md) (DOI: 10.1080/19932820.2026.2732308)
- [Trump administration drug-pricing plan: Did Novo Nordisk get an extra financial win?](https://medichelpline.com/clinical-feed/stat-news-0-stat-did-the-trump-administration-just-cut-novo-a-huge-financial-win.md)
- [Global policy drivers of national HPV vaccine introductions (2006–2025)](https://medichelpline.com/clinical-feed/pubmed-42770688.md) (DOI: 10.1080/14760584.2026.2736328)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.